Summary of Findings in ALCL of T- and Null-Cell Type
| Cases . | Age/Sex . | TIA-1 . | PRF . | CD4 . | CD8 . | CD56 . | CD57 . | Other Antigens* . | NPM-ALK . |
|---|---|---|---|---|---|---|---|---|---|
| 1. CS | 9/M | + | + | + | − | − | − | CD2/3/7+, CD5− | ND |
| 2. CS | 28/M | + | + | + | − | − | − | CD2/3/7/43/45R0+, CD5− | ND |
| 3. CS | 53/F | − | + | + | − | − | − | CD45R0+, CD3ε/43− | − |
| 4. CS | 64/M | − | (+) | + | − | − | − | CD3ε/43+, CD45R0− | ND |
| 5. CS | 16/M | + | + | − | + | − | − | CD3/3ε/7+, CD5− | + |
| 6. CS | 62/M | + | + | + | (+) | − | − | CD2/3/5/7+ | ND |
| 7. CS | 11/M | + | + | − | − | − | − | CD2/3/7/43/45R0+, CD5−, β−, δ− | + |
| 8. CS | 5/M | + | + | − | − | − | − | CD5+, CD3/3ε/43/45R0− | ND |
| 9. CS | 28/M | + | + | − | − | + | − | CD3ε/43+, CD2/3/5/7/16−, β−, δ− | + |
| 10. CS | 30/F | + | + | − | − | − | − | CD43+, CD3ε/45R0− | + |
| 11. CS | 35/F | + | + | ND | − | − | − | CD3ε/43/45R0− | + |
| 12. CS | 27/M | + | (+) | − | − | − | − | CD2/3/3ε/5/7−, β−, δ− | ND |
| 13. CS | 14/F | (+) | + | − | − | − | − | CD3ε/43/45R0− | + |
| 14. CS | 41/F | (+) | + | − | − | − | − | CD3ε/43/45R0− | − |
| 15. CS | 49/M | + | − | − | − | − | − | CD3ε/43/45R0− | − |
| 16. CS | 20/F | − | − | + | − | − | − | CD3ε/43/45R0+ | ND |
| 17. CS | 52/M | − | − | − | (+) | − | − | CD2/3/5/43/45R0+, CD7−, β−, δ− | ND |
| 18. CS | 43/M | − | − | + | (+) | − | − | CD3ε/43/45R0+ | + |
| 19. CS | 59/M | − | − | + | + | − | (+) | CD3ε/43+, CD45R0− | + |
| 20. HR | 18/M | + | + | + | − | − | − | CD43/45R0+, CD3ε− | ND |
| 21. HR | 13/M | + | + | + | − | − | − | CD43/45R0+, CD3ε− | + |
| 22. HR | 31/M | + | (+) | + | − | − | − | CD3/43/45R0+, CD2/5/7− | ND |
| 23. HR | 44/F | + | + | (+) | − | − | − | CD43/45R0+, CD3ε− | ND |
| 24. HR | 25/M | + | + | ND | + | ND | ND | CD43/45R0+, CD3ε− | ND |
| 25. HR | 13/M | (+) | + | − | − | − | − | CD2/5/7+, β+, CD3/3ε− | − |
| 26. SCP | 14/F | + | + | ND | + | − | − | CD3ε/43/45R0+ | ND |
| 27. SCP | 7/F | + | + | − | − | − | − | CD3ε/43/45R0+ | ND |
| 28. PC | 29/M | − | − | + | − | − | − | CD2/3/3ε/5/43+, CD7/45R0−, β−, δ− | − |
| 29. PC | 48/M | − | − | + | − | − | − | CD3ε/43/45R0+ | ND |
| 30. PC | 43/M | − | − | + | − | − | − | CD43+, CD3ε/45R0− | − |
| 31. HIV | 3/F | + | − | + | − | − | − | CD2/3/5/7/43+, β+, CD45R0−, δ− | − |
| 32. HIV | 1/M | + | − | − | − | − | − | CD3ε/43/45R0+ | − |
| 33. HIV | 13/F | − | − | − | − | − | − | LCA+, CD3ε/43/45R0/68− | − |
| Cases . | Age/Sex . | TIA-1 . | PRF . | CD4 . | CD8 . | CD56 . | CD57 . | Other Antigens* . | NPM-ALK . |
|---|---|---|---|---|---|---|---|---|---|
| 1. CS | 9/M | + | + | + | − | − | − | CD2/3/7+, CD5− | ND |
| 2. CS | 28/M | + | + | + | − | − | − | CD2/3/7/43/45R0+, CD5− | ND |
| 3. CS | 53/F | − | + | + | − | − | − | CD45R0+, CD3ε/43− | − |
| 4. CS | 64/M | − | (+) | + | − | − | − | CD3ε/43+, CD45R0− | ND |
| 5. CS | 16/M | + | + | − | + | − | − | CD3/3ε/7+, CD5− | + |
| 6. CS | 62/M | + | + | + | (+) | − | − | CD2/3/5/7+ | ND |
| 7. CS | 11/M | + | + | − | − | − | − | CD2/3/7/43/45R0+, CD5−, β−, δ− | + |
| 8. CS | 5/M | + | + | − | − | − | − | CD5+, CD3/3ε/43/45R0− | ND |
| 9. CS | 28/M | + | + | − | − | + | − | CD3ε/43+, CD2/3/5/7/16−, β−, δ− | + |
| 10. CS | 30/F | + | + | − | − | − | − | CD43+, CD3ε/45R0− | + |
| 11. CS | 35/F | + | + | ND | − | − | − | CD3ε/43/45R0− | + |
| 12. CS | 27/M | + | (+) | − | − | − | − | CD2/3/3ε/5/7−, β−, δ− | ND |
| 13. CS | 14/F | (+) | + | − | − | − | − | CD3ε/43/45R0− | + |
| 14. CS | 41/F | (+) | + | − | − | − | − | CD3ε/43/45R0− | − |
| 15. CS | 49/M | + | − | − | − | − | − | CD3ε/43/45R0− | − |
| 16. CS | 20/F | − | − | + | − | − | − | CD3ε/43/45R0+ | ND |
| 17. CS | 52/M | − | − | − | (+) | − | − | CD2/3/5/43/45R0+, CD7−, β−, δ− | ND |
| 18. CS | 43/M | − | − | + | (+) | − | − | CD3ε/43/45R0+ | + |
| 19. CS | 59/M | − | − | + | + | − | (+) | CD3ε/43+, CD45R0− | + |
| 20. HR | 18/M | + | + | + | − | − | − | CD43/45R0+, CD3ε− | ND |
| 21. HR | 13/M | + | + | + | − | − | − | CD43/45R0+, CD3ε− | + |
| 22. HR | 31/M | + | (+) | + | − | − | − | CD3/43/45R0+, CD2/5/7− | ND |
| 23. HR | 44/F | + | + | (+) | − | − | − | CD43/45R0+, CD3ε− | ND |
| 24. HR | 25/M | + | + | ND | + | ND | ND | CD43/45R0+, CD3ε− | ND |
| 25. HR | 13/M | (+) | + | − | − | − | − | CD2/5/7+, β+, CD3/3ε− | − |
| 26. SCP | 14/F | + | + | ND | + | − | − | CD3ε/43/45R0+ | ND |
| 27. SCP | 7/F | + | + | − | − | − | − | CD3ε/43/45R0+ | ND |
| 28. PC | 29/M | − | − | + | − | − | − | CD2/3/3ε/5/43+, CD7/45R0−, β−, δ− | − |
| 29. PC | 48/M | − | − | + | − | − | − | CD3ε/43/45R0+ | ND |
| 30. PC | 43/M | − | − | + | − | − | − | CD43+, CD3ε/45R0− | − |
| 31. HIV | 3/F | + | − | + | − | − | − | CD2/3/5/7/43+, β+, CD45R0−, δ− | − |
| 32. HIV | 1/M | + | − | − | − | − | − | CD3ε/43/45R0+ | − |
| 33. HIV | 13/F | − | − | − | − | − | − | LCA+, CD3ε/43/45R0/68− | − |
+, majority (>50%) of the tumor cells are positive; (+), less than 50% but more than 5% of the tumor cells are positive; −, tumor cells are negative.
Abbreviations: CS, classical systemic form of ALCL; F, female; HIV, human immunodeficiency virus-associated ALCL; HR, histiocyte-rich variant of ALCL; M, male; ND, not done; NPM-ALK, RT-PCR assay for NPM-ALK fusion transcript of t(2; 5) translocation; PC, primary cutaneous form of ALCL; PRF, perforin; SCP, small cell-predominant variant of ALCL; β and δ, T-cell receptor (TCR) beta and delta chains; CD3ε, CD3 epsilon chain as detected with DAKO polyclonal CD3 antibody.
All of the cases were CD30+. No one of these cases showed B-cell marker (CD19, CD22, or CD20/L26) positivity.